To evaluate the possible mechanisms, related to E2F1 expression upregulation after treatment with DBF, we used GSEA to identify GO biological processes associated with E2F1 expression in AML cells by comparing the top 20% of AML samples with the highest E2F1 expression with the rest of the samples from the GSE37642 dataset [40]. This evidence concerns the gene E2F1 and acute myeloid leukemia.